3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma, Follicular
2
Head and Neck Neoplasms
2
Recurrence
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
13
Etoposide
10
Prednisone
8
Doxorubicin
8
Whole-Body Irradiation
7
Vincristine
7
Rituximab
7
Peripheral Blood Stem Cell Transplantation
7
Melphalan
7
Brentuximab Vedotin
7
romidepsin
6
fludarabine phosphate
6
Mycophenolic Acid
6
fludarabine
5
Lenalidomide
5
Gemcitabine
5
Cytarabine
5
10-propargyl-10-deazaaminopterin
5
Tacrolimus
4
Granulocyte Colony-Stimulating Factor
4
Carmustine
4
Busulfan
4
Antilymphocyte Serum
4
pembrolizumab
3
etoposide phosphate
3
carmustine, poliferprosan 20 drug combination
3
Vorinostat
3
Sirolimus
3
Nivolumab
3
Filgrastim
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, T-Cell
×
duvelisib
×
Clear all
NCT03372057
2025-03-07
PRIMO
SecuraBio
Phase 2
Completed
156 enrolled
21 charts